Lupin launches Luforbec 100/6 μg pMDI
It is the first branded generic alternative to Fostair 100/6 μg pMDI for the treatment of asthma and COPD in the UK
Following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, Lupin Healthcare has launched Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in a statement.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal). Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US, added the statement.
- Advertisement -